How profitable is UFP Technologies Inc. (UFPT)?

In FY 2025 (10-K), UFPT converted $602.8M of revenue into a 28.3% gross margin, 15.3% operating margin, and $91.9M in free cash flow (15.2% FCF margin).

Stock Ratings / Health Care / UFPT / financials

INSP (65) XRAY (32) LMAT (67) KMTS (50) ⌘ Pro Terminal →

UFP Technologies Inc. (UFPT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$283.97 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $284.55

UFP Technologies Inc. (UFPT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (28.3% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UFPT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, UFP Technologies Inc. (NASDAQ: UFPT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $283.97 (-0.19% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UFPT ranks #42 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UFPT compare to INSP and XRAY in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), UFPT carries a Roarable B (74/100 RQD), trailing P/E of 33.3x, gross margin of 28.3%, and ROIC of 13.9%. By comparison, INSP (Inspire Medical Systems Inc.) holds a C grade (65/100 RQD, P/E 14.2x, ROIC 6.0%, cap $1.97B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UFPT?

▼

Per UFPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914156), UFP Technologies Inc. generated $602.8M in revenue (+19.5% YoY), $68.3M in net income, and $91.9M in free cash flow against $655.1M in total assets and $123.0M in total debt. Key quantitative strengths: Strong cash generator (28.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $284.57 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 15.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 Quant Analysts Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UFPT)Realized 20D OHLCV Swing Band: ±6.9%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY UFPT SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 8.31 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 15.2% FCF Margin ($91.9M FCF) & 28.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$294.29-1% Next Q

Q2 (-2Q)

Grade A-$291.34+1.2% Next Q

Q3 (-1Q)

Grade B+$294.84-3.7% Next Q

Current

Grade B$283.97+7.3% Hist 90D α

Trajectory: A (82) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UFPT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, UFPT faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 25.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($291.00) or 200D SMA ($249.56) invalidates the momentum regime and cuts Target Base ($304.42) toward Bear Floor ($232.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UFPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UFPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How UFPT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$91.9M (15.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $400.1M

FY24

Rev $504.4M

FY25

Rev $602.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$602.8M	28.3%	15.3%	$68.3M	$91.9M	13.9%
FY 2024	$504.4M	29.1%	16%	$59.0M	$56.9M	12.6%
FY 2023	$400.1M	28.3%	14.4%	$44.9M	$41.3M	13.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UFPT)

✓Walkthrough of UFPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UFPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.48%⚡ TESTING RESISTANCE

2026-11-03O $293.3H $293.3L $284.0C $284.0VOL 85.4K

RES: $297.2SUP: $281.1SMA50: $291.0SMA200: $249.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UFPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UFPT Butterfly Map → + Track UFPT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.7%/yr Implied 5Y Growth

vs. +19.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UFPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UFPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UFPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UFPT)

Health Care Rank #42 of 1015 ⚔️ INSP vs UFPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UFPT vs. INSP, XRAY, LMAT, KMTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, UFP Technologies Inc. (UFPT) ranks #42 by composite RQD confidence (74/100, grade B) and #240 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UFPT ACTIVE UFP Technologies Inc.	B	74/100	33.3x	28.3%	13.9%	-0.19%	$2.20B	Benchmark Subject
INSP Inspire Medical Systems Inc.	C	65/100	14.2x	85.4%	6.0%	-1.31%	$1.97B	/insp-vs-ufpt →
XRAY DENTSPLY SIRONA Inc.	E	32/100	—	50.0%	-11.0%	+3.88%	$1.90B	/xray-vs-ufpt →
LMAT LeMaitre Vascular Inc.	C+	67/100	33.8x	71.5%	14.7%	+0.40%	$1.85B	/lmat-vs-ufpt →
KMTS Kestra Medical Technologies Ltd.	D	50/100	—	51.4%	-35.0%	+0.40%	$1.77B	/kmts-vs-ufpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000914156 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), UFP Technologies Inc. (UFPT) reported GAAP revenue of $602.8M (+19.5% vs. FY2024 revenue of $504.4M , and +50.7% cumulative change since FY2023) , GAAP net income of $68.3M, operating cash flow of $91.9M, and free cash flow of $91.9M (+61.4% YoY). On the balance sheet, UFPT closed FY2025 with $655.1M in total assets against $123.0M in total debt (Altman Z-Score: 8.31, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$602.8M	$68.3M	$91.9M	$91.9M	$655.1M	$123.0M
FY2024 (FY)	2024-12-31	$504.4M	$59.0M	$66.6M	$56.9M	$629.0M	$176.9M
FY2023 (FY)	2023-12-31	$400.1M	$44.9M	$41.3M	$41.3M	—	—

3. UFPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UFPT compare to INSP and XRAY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UFPT?

Where is UFPT trading relative to its 50-day, 200-day, and 52-week technical levels?

UFPT last traded at $283.97 (-0.19% on volume of 85,502 shares), positioning the stock -2.42% below its 50-day simple moving average ($291.00) and +13.79% above its 200-day simple moving average ($249.56). Across its 52-week range of $173.86 to $338.71, UFPT sits at the 66.8% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($264.38 to $303.56).

Direct Sub-Reports: UFPT RQD Cockpit UFPT 12M Forecast UFPT Earnings & Move UFPT Dividends & DRIP UFPT Insiders & 13F UFPT Whale Options UFPT Profit Sankey UFPT News & Why

ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ SEC XBRL & RQD VERIFIED

UFPT — UFP Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

UFP Technologies Inc. (UFPT) earns a live Roarable RQD composite score of 74/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $283.97 (-0.19% 1D, market capitalization $2.20B).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 13.9%, gross margin of 28.3%, operating margin of 15.3%, and free cash flow yield of 4.05%.
Whale 13F & Options Flow (10/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.31, Piotroski F-Score of 9/9, and Debt/Equity of 0.29x.

2. Business Model, Unit Margins & SEC Financial Trajectory

UFP Technologies Inc. (UFPT) is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. The company carries a market capitalization of $2.3B. — for specific product lines, customer base, or revenue model detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), UFP Technologies Inc. (UFPT) reported $602.8M in annual revenue (up from $504.4M in FY2024, +19.5% YoY) and $68.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($400.1M revenue, $44.9M net income) through FY2025, UFPT scaled operating cash flow to $91.9M and free cash flow to $91.9M, backed by $655.1M in total assets against $123.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 74/100): Strong cash generator (28.3% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $173.86 – $338.71 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 33.3x trailing P/E and 25.7x EV/EBITDA against 15.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— there are no upstream or downstream links, no sector correlations, and no proprietary signals recorded. The Health Care / Medical-Dental Instruments classification is noted, but no ripple mapping is provided.

Key Question #1: Can UFPT sustain or expand its 15.3% operating margin and 13.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $602.8M and free cash flow of $91.9M, how will capital allocation balance growth reinvestment against $123.0M in total debt?
Key Question #3: How sensitive is UFPT's 28.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UFPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for UFP Technologies Inc. (UFPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UFPT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

2 Reasons to avoid UFPT and 1 stock to buy instead

Yahoo Finance report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

UFP Technologies: Re-Rated As Organic Growth Returns (NASDAQ:UFPT)

Seeking Alpha report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

UFP Technologies (UFPT) Q3 earnings report preview: what to look for

TradingView report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Do UFP Technologies' (NASDAQ:UFPT) Earnings Warrant Your Attention?

Moomoo report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A results call is set for Nov. 4 at 8:30 a.m.

Stock Titan report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 1d ago

Congress Asset Management Co. Cuts Stock Position in UFP Technologies, Inc. $UFPT

MarketBeat report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 2d ago

Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

Simply Wall St report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

TradingView report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UFPT Bull vs. Bear Conversation Board — What's Your Call at $283.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UFPT 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $335.71 (+18.0%)

📌 Pinned Debate

Revenue grew from $400.1M to $602.8M in two years while the balance sheet strengthened, with Piotroski F-Score 9/9 and Altman Z-Score 8

Here is why I am bullish on UFPT here at $284.50: Revenue grew from $400.1M to $602.8M in two years while the balance sheet strengthened, with Piotroski F-Score 9/9 and Altman Z-Score 8.31.. Compare UFPT's 15.3% operating margin and 13.9% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $270.27 are getting bought.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 74/100 quality, though with 1.0 beta I'm scaling in with half-size at $284.50 and keeping dry powder in case we test $264.59.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $224.76 (-21.0%)

Spot @ $284.50

At a P/E (TTM) of 33.3 and EV/EBITDA of 25.7 against a 4.05% FCF yield, the valuation prices in continued growth with little margin for

Sitting on the sidelines or leaning short UFPT above $284.50. At a P/E (TTM) of 33.3 and EV/EBITDA of 25.7 against a 4.05% FCF yield, the valuation prices in continued growth with little margin for error.. Until Fundamental Cash Engine (17/20) and FCF yield (4.05%) inflect higher, upside is capped near $338.71.